Literature DB >> 11371939

Bradykinin induced mitogenesis of androgen independent prostate cancer cells.

L Barki-Harrington1, Y Daaka.   

Abstract

PURPOSE: We investigated the mitogenic role of bradykinin (BK) in the regulation of the extracellular signal regulated kinase 1 and 2 (ERK), and the growth of androgen insensitive prostate cancer cells.
MATERIALS AND METHODS: Androgen insensitive PC3 cells were used in these studies. BK and epidermal growth factor were used as mitogens. The chemical inhibitors tyrphostin AG1478 (epidermal growth factor receptor inhibitor), bisindolylmaliemide (protein kinase C inhibitor) and PD98059 (MEK inhibitor) were applied 30 minutes before stimulation with agonist. Down-regulation of protein kinase C was accomplished by incubating cells overnight with phorbol ester. Cell proliferation was measured using WST-1 reagent and the trypan blue exclusion assay. ERK expression and activation were assayed by immunoblotting for total and phosphorylated ERK.
RESULTS: Bradykinin induced the proliferation of PC3 cells in a pathway that requires the activation of ERK. The BK regulated activation of ERK was time and dose dependent, yielding a maximal response at the same concentration range that elicits cellular growth. BK exerted its effect on ERK activation via a protein kinase C and epidermal growth factor receptor dependent pathway. Inhibition of the kinase activity of protein kinase C or epidermal growth factor receptor eliminated BK induced ERK activation. Furthermore, the inhibition of epidermal growth factor receptor transactivation abolished BK induced cell proliferation.
CONCLUSIONS: Our results show that BK induces the proliferation of androgen insensitive prostate cancer cells and suggest a possible pathophysiological role for BK in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371939     DOI: 10.1097/00005392-200106000-00081

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

2.  GPRC6A regulates prostate cancer progression.

Authors:  Min Pi; L Darryl Quarles
Journal:  Prostate       Date:  2011-06-16       Impact factor: 4.104

Review 3.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

4.  B1 but not B2 bradykinin receptor agonists promote DU145 prostate cancer cell proliferation and migration.

Authors:  N Naidu; J H Botha; S Naidoo
Journal:  Afr Health Sci       Date:  2014-09       Impact factor: 0.927

5.  Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.

Authors:  Neil E Bhola; Maria L Freilino; Sonali C Joyce; Malabika Sen; Sufi M Thomas; Anirban Sahu; Andre Cassell; Ching-Shih Chen; Jennifer R Grandis
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

6.  Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells.

Authors:  Liza Barki-Harrington; Angela L Bookout; Gaofeng Wang; Maria E Lamb; L M Fredrik Leeb-Lundberg; Yehia Daaka
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

7.  Pharmacological characterization of canine bradykinin receptors in prostatic culture and in isolated prostate.

Authors:  Dinesh Srinivasan; Leah R Burbach; Donald V Daniels; Anthony P D W Ford; Anindya Bhattacharya
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

8.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

9.  Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.

Authors:  Michelle L Thompson; Juan M Jimenez-Andrade; Stephane Chartier; James Tsai; Elizabeth A Burton; Gaston Habets; Paul S Lin; Brian L West; Patrick W Mantyh
Journal:  Pain       Date:  2015-09       Impact factor: 7.926

10.  Mitogen Activated Protein kinase signal transduction pathways in the prostate.

Authors:  Paul D Maroni; Sweaty Koul; Randall B Meacham; Hari K Koul
Journal:  Cell Commun Signal       Date:  2004-06-25       Impact factor: 5.712

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.